Ethical Committee approval has been obtained from ethics committee of Faculty of Medicine, Alexandria University.~Assigning an informed consent for agreement of participation should be taken by all participants in this clinical study.~Heart failure patients with reduced and mildly reduced ejection fraction will be recruited from Alexandria Main University Hospital (AMUH), private hospitals and clinics.~A Blood sample will be collected from 60 patients as baseline to test for N-terminal Pro-B-type Natriuretic Peptide.~The same 60 patients will take Empagliflozin for 6 months.~Another blood sample will be taken from the same 60 patients to test the effect on N-terminal Pro-B-type Natriuretic Peptide after Empagliflozin administration.~The appropriate statistical test will be hold according to study design and parameters to evaluate the significant results.~Results conclusion discussion and recommendations will be given.
This study aims to evaluate the relationship between NT-proBNP and empagliflozin effects in patients with chronic heart failure with mildly reduced ejection fraction (HFmrEF 41-49%) and reduced ejection fraction (HFrEF ≤40%) whether diabetic or non-diabetic patients.